glp 1 agonist contraindication Contraindications for switching GLP-1 Medications: Everything You Need

Here's what clinicians should know.

The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations globally

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

Models suggest societal upheaval from anti-obesity medicines but impacts are hard to predict.

Learn About Their Benefits and Effectiveness.

More recent evidence is expanding their benefits to heart failure with preserved ejection fraction and clinically important renal outcomes in patients with and without diabetes